BUZZ-Valneva股价暴跌,因莱姆病疫苗后期试验未达标

路透中文
Yesterday
BUZZ-Valneva股价暴跌,因莱姆病疫苗后期试验未达标

3月23日 - ** ValnevaVLS.PA的股票在自动停止交易前暴跌了29%。此前,这家法国制药商及其美国同行辉瑞PFE.N在一项关键实验性疫苗的后期试验中未能达到预先确定的统计标准。

** 名为 PF-07307405 的莱姆病疫苗 (link) 在第一次分析中未能达到主要目标,原因是试验中累积的莱姆病病例少于预期,导致数据点数量较少。

** 公司表示,第二次计划分析达到了标准,增强了辉瑞公司 "对疫苗潜力 "的信心

** 如果跌势持续,Valneva股价将创下自8月底以来的最大单日跌幅。

(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10